ROCKVILLE, Md., Oct. 27, 2011 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that Stanley C. Erck, President and Chief Executive Officer of Novavax, testified this afternoon on behalf of BIO to support its initiative for reducing filing and prosecution costs for international patent protection of biotechnology discoveries.
